Manchester Heart Centre researchers recruit first UK patient to trial comparing stents in coronary artery stenosis sufferers
Dr Farzin Fath-Ordoubadi, Consultant Cardiologist, and his
research team at the
Manchester Royal Heart Centre for recruiting the first UK
patient to the Merit Study.
Merit is an open label, randomised clinical study to compare two
types of marketed stents in patients with coronary artery
This condition is triggered as a result of narrowing of the
blood vessels that supply blood to heart muscles, called the
coronary arteries, causing poor blood flow.
In order to improve the blood flow and to relieve symptoms,
doctors perform a procedure called angioplasty, where a small
balloon is inflated inside the artery to open it up. To hold the
artery open, a tiny metallic cylindrical mesh, called a stent, is
implanted during angioplasty.
There is a risk of the stent re-blocking over a few months or
years and so the stent is coated with a device known as a Drug
Eluting Stent. BioMime and Xience are among such devices which are
already used in day-to-day clinical practice.
Dr Farzin Fath-Ordoubadi said: "The purpose of this
study is to evaluate the safety and efficacy of the BioMime device
as compared with Xience family device. It is mainly scientific and
such comparative studies are performed routinely to evaluate scope
of improvement in the treatment of the disease in various aspects
and the device.
"I'd like to thank the dedication of the Manchester Heart Centre
research team and the cardiology team for working so hard to
recruit the first UK patient to this trial. This once again
illustrates our excellent performance in managing clinical